{"name":"Mereo BioPharma","slug":"mereo-biopharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BCT197","genericName":"BCT197","slug":"bct197","indication":"Other","status":"phase_2"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Alvelestat oral tablet - dose 1","genericName":"Alvelestat oral tablet - dose 1","slug":"alvelestat-oral-tablet-dose-1","indication":"Alpha-1 antitrypsin deficiency-associated lung disease","status":"phase_2"}]}],"pipeline":[{"name":"BCT197","genericName":"BCT197","slug":"bct197","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alvelestat oral tablet - dose 1","genericName":"Alvelestat oral tablet - dose 1","slug":"alvelestat-oral-tablet-dose-1","phase":"phase_2","mechanism":"Alvelestat is a selective inhibitor of neutrophil elastase, an enzyme involved in the degradation of lung tissue.","indications":["Alpha-1 antitrypsin deficiency-associated lung disease","Acute respiratory distress syndrome"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxNV0IxQ3hLM1V6SVNDWUhZNFc5Y0tlUklZZUluakdVRnBLdVJOeU56Q0FKOVdyZ2NYbWZqVGNsMURCMXEzWHJSYUJrX3FzSUlsUEktM2RRak9xSnl1OENCeFF3VzdDaHp2Y0FJVy12N2hFVzBTY1FzV3RmdWZvN0RYYU1Sa20xMGZRM2p2UTlYMjNjMVpsTUV1TG5YOEZNWnNYd0RSVWZCTTdybTFnVFJBeEhwV3lWUW5fa1ltdEhIWFVEVm0ybGhteVI5ajJXZHJlVzFEZklrU0tfUVMtYkMyS0FVcDhtNEdRY0ZWR250RGRzQS1n?oc=5","date":"2026-03-19","type":"pipeline","source":"GlobeNewswire","summary":"Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire","headline":"Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-17","type":"trial","source":"simplywall.st","summary":"A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update - simplywall.st","headline":"A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNQjh3eW9RQlJrU25rZG51dktZeVRtalFHZUtXb2QxNjRaMU9zcTk5SkhIYS1LaGRXa0dlY013VXc1cHByU1BGNlJsdjlCYW16T3dHVUx4NDVCczFhNURrMjBzTlVvNFFFTWttcWJ6UUNadUJNWGhORzkzTDY2dXNnNGNsNmV0MTg?oc=5","date":"2026-01-12","type":"pipeline","source":"Yahoo Finance","summary":"Mereo BioPharma Provides Corporate Update - Yahoo Finance","headline":"Mereo BioPharma Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPazU1UldNWGQzY2kzTXItdGRWTkVoaVB2ZDkxRjJhVkZsMGhPUnNTVHNLcTR3OUQ5YU05X2EtRGVIOWNtRjZxa0FRMUp0SnRRSjVUUmNQc1JHZnNqXzNwZENIZ1d1VG9nSDRvOFJkTkZzUWxQWnRmVDVUNFJGS0szSmNtTzREWW5OSU5aOFBFekhLQ0dh?oc=5","date":"2026-01-12","type":"pipeline","source":"Stock Titan","summary":"Rare disease drug maker maps next steps as cash runway to 2027 - Stock Titan","headline":"Rare disease drug maker maps next steps as cash runway to 2027","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOWjlQVmNBbVBsTlNiYzQ5R1dvanUyZjB3ZDZGUjIxWDBnWXBpWGRUbHItakl5eGFUWkpRTW5CVmJGRTZEa0ViSTZJVW5DMlB2VjFGYWxwcG9ZbEEyTjlKOWlTbXQzTHdOLXB0WFBLMFVXN0p6QllFdjhvVVlBdHhKRW9RSW5YbFU5djM3UjF0VTh4dEc4U2k3cmhKYWNmdnVyby1XclF4TGVEaV9Sci1HX2UwN3ljQkE0OWpuLWJwYlUwWVNYTGFz?oc=5","date":"2026-01-04","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures - Genetic Engineering and Biotechnology News","headline":"StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPbElDeDZnc1M5R2o3d216S2FBekFDQ0FPcE5fTDhQU1ZIZ1VCUVVDQXdSX2F3UFN3Q2xxSkVHdmF4eGtGWlVCUWlWMG9hY0g4NUNnZlZQbkVFWXZQYjFHanR0TlR5ZXdNTDdnNlNkNVFPdEJ6SEF6RnVXTHJGREEzRHhnWEotVFBZbnE3OTRHNlljSGgySlJEd25fdG4wSnhrZjNkWEdxcFM4aFRUaVpMd05n?oc=5","date":"2025-12-30","type":"trial","source":"The Pharma Letter","summary":"Ultragenyx and Mereo tank as Phase III setrusumab trial disappoints - The Pharma Letter","headline":"Ultragenyx and Mereo tank as Phase III setrusumab trial disappoints","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxORy1DQ0xNUHFEeFZfcE5sU084Z3BQRTNoeTBPeVBEUUNJSmVCU3prSWNYeGVMRW0tTS1GMnJiTmFFNEpSOW5UYWlzN29BQTIwX3RSQVQxempkRlpGLWZ2ZUJWYUlOOWtIZ2Y4OE5zNElDVGtQeTk5LXhVdFRyamc2c01DMEFySGpNbnFTZkhDeTNuRUVGejlnaWM2NXIyNlk?oc=5","date":"2025-12-30","type":"trial","source":"finviz.com","summary":"RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - finviz.com","headline":"RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxPUGk3MUZLWWdyZnVMSG9oaGh4MTNOelRXakxvNzFaY2M5OEt2Q0t2NUU3RUxKQ3pjOGR1NVRIQ1Fxa3FHVmlBRmlpdk5pM0tGUDJRM01CWFRXMjJDaDN4MHVRZ19vOTVCWTRNb2owdnA3TGdNM1JLaWRxams4Y0NRbDU0cTBrZjM2aDVILVkwWUgyMjZXUTZJOEcxTzkxUFZxWDExblRzU3N6T1h6SXJFQTVHbnNGeEYteVJTZGFTcFRxQ0FzTVdaU2dsNUdudnIzak9TWGczQXFnNDY4RVRDNzdZUDBHenVxWHlVazR3NW9pNkJBY0lJVi1CY1gzSjFJcTVqZjFoMG1zTzRFbWRTd2lKMGJ1WlU?oc=5","date":"2025-12-30","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE50d243czBiOTRnVm10UFVWejZWajYtSTBqakVJM2ZLWEt2THVadmxWelFLRTRnRlhMd0VpeWdLR0JUY1BpWUJhZHpmamtIbDVrSm1n?oc=5","date":"2025-12-29","type":"trial","source":"FirstWord Pharma","summary":"Ultragenyx, Mereo plummet after two brittle bone trials fail - FirstWord Pharma","headline":"Ultragenyx, Mereo plummet after two brittle bone trials fail","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOT25HdWNWdllYdVhCa2xBWVlrVi1fZEhzNjVMNjYwNFBQa1hLNHRGaFl6a3gyNFlrV3g4WVViekVQTHRyNTVsd1FjM3lrNzJYRndxbi1RN0I4M202UURWSkFJS1ZROWlIbVpLZjE2SDJiM1VfRlV3N2JXNU1URW5zNUZ1cm5SQlVpQVc2QXZEWllaWUtMMUxmbUxn?oc=5","date":"2025-12-29","type":"trial","source":"TipRanks","summary":"Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials - TipRanks","headline":"Mereo Biopharma Stock (MREO) Collapses over 90% after Failed Trials","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPYUNEQm1kTE9HWk9QeWJ1MEt5LVFfU2lUODktTEp0MFVZclZxNDhHTkpVSHd6aEwwanRlVVEya3o5UFBSS1lWRGw0dnR5WGRSenFzOTdHTFRMWXg0ZFRMVWQzenRhUVZfREx2eWRId3hHOHdWVUxqT1FpcXhNWkJZcUFLT25UUVMwQ0JzTlRCaldOLVNwdGRPa1kyTU1jYWVyaFhPY01fTEFXZDhZVmdWXzhSSWdhLVpFMkh2UzYxa2xiQzNKNlBtdUxyYXVlVmc2NlRTNVQxUV9sZElMTUFwSk5oLWpfY0tHWXMyWXpOT2E0SlRTVkFJeWFR?oc=5","date":"2025-12-29","type":"pipeline","source":"Benzinga","summary":"Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga","headline":"Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNY0xJMlZPV281N05aeTZYQmFNeUc5a2hBc2QwdWhTSG55c0xVb1BnemhzdkRYUXZzcWtnZjAza3doRDZTWGdqTzdEX0l5bWlXbFZzTHlOWXZEMVZzUVBHTkZSZVdSSHRLamVhN05BQWxUcUVaZEswUHhoMTJ0LVBiUHB2Nl81cm5waUpfT3JOZDRZeVBHOXAwbHAxWUZ3NmxJZTNIYjFTcFBweGFrQ3d4TVlnV0NNMlUxZUtCSy1HX2dYdUxhdkVCWGd4c2hEMW8?oc=5","date":"2025-11-20","type":"trial","source":"Seeking Alpha","summary":"Ultragenyx And Mereo BioPharma: Considering Their Brittle Bone Disease Phase 3 Trials' Prospect - Seeking Alpha","headline":"Ultragenyx And Mereo BioPharma: Considering Their Brittle Bone Disease Phase 3 Trials' Prospect","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}